Advanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Units

Simple item page
dc.contributor.authorBouda, Gabrielle C.
dc.contributor.authorTraore, Fousseyni
dc.contributor.authorCouitchere, Line
dc.contributor.authorRaquin, Marie-Anne
dc.contributor.authorGuedenon, Koffi M.
dc.contributor.authorPondy, Angele
dc.contributor.authorMoreira, Claude
dc.contributor.authorRakotomahefa, Mbola
dc.contributor.authorHarif, Mhamed
dc.contributor.authorPatte, Catherine
dc.date.accessioned2022-05-17T11:59:51Z
dc.date.available2022-05-17T11:59:51Z
dc.date.issued2019-11
dc.descriptionBurkitt Lymphoma (BL) is the most frequent non-Hodgkin lymphoma (NHL) in children and accounts for 50%-60% of childhood NHLen_US
dc.description.abstractPurpose To evaluate the results of an intensive polychemotherapy regimen for Burkitt lymphoma (BL) in sub-Saharan African pediatric centers. Patients and Methods Children with advanced-stage BL (stages II bulky, III, and IV) treated with the GFAOP–Lymphomes Malins B (GFALMB) 2009 protocol in 7 centers between April 2009 and September 2015 were prospectively registered. Treatment regimen contained a prephase with cyclophosphamide followed by 2 induction courses (cyclophosphamide, vincristine, prednisone, high-dose methotrexate [HDMTX]), 2 consolidation courses (cytarabine, HDMTX), and a maintenance phase only for stage IV. HDMTX was given at the dose of 3 g/m2. Results Four hundred patients were analyzed: 7% had stage II bulky, 76% stage III, and 17% stage IV disease. Median age was 7.3 years, and sex ratio was 1.9:1 (male:female). A total of 221 patients received the whole protocol treatment and 195 achieved complete remission (CR), 11 of them after a second-line treatment. Treatment abandonment rate was 22%. One hundred twenty-five patients died, of whom 49 deaths were related to treatment toxicity. A total of 275 patients are alive, including 25 despite treatment abandonment, but only 110 are known to be in CR with a follow-up . 1 year, indicating a high rate of loss to follow-up. Twelve-month overall survival (OS) was 60% (95% CI, 54% to 66%) and 63%, 60%, and 31%, respectively, for stage II bulky, III, and IV. Patients with stage III disease who started second induction course within 34 days had OS of 76%, versus 57% (P = .0062) beyond 34 days. Coclusion The GFA-LMB2009 protocol improved patients’ survival. Early dose intensity of treatment is a strong prognostic factor. Improving supportive care and decreasing loss to follow-up are crucial.en_US
dc.description.sponsorshipSupported by Institut Gustave Roussy, Villejuif, France; Ligue Nationale Contre le Cancer, France; Societ´ e Française des Cancers de l ´ ’Enfant; Societ´ e Française de P ´ediatrie; Soci ´ et´ e Internationale d ´ ’Oncologie Pediatrique; ´ Œuvres Hospitalieres Françaises de l ` ’Ordre de Malte, Paris, France; Fondation Sanofi-Espoir, Paris, France; Association Pathologie, Cytologie et Developpement, France; and Association Lalla Salma, ´Rabat, Morocco. World Banken_US
dc.identifier.citationBouda et al. (2019) Advanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Units: Results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d’Oncologie Pédiatrique. Journal of Global Oncology, pp. 1-10. DOI: 10.1200/JGO.19.00172en_US
dc.identifier.urihttp://hdl.handle.net/123456789/1444
dc.language.isoenen_US
dc.publisherResearch Gateen_US
dc.relation.ispartofseriesDOI: 10.1200/JGO.19.00172;10
dc.subjectBurkitt Lymphoma (BL)en_US
dc.subjectnon Hodgkin lymphoma (NHL)en_US
dc.titleAdvanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Unitsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Advanced_Burkitt_Lymphoma_in_Sub-Saharan_Africa_Pe.pdf
Size:
855.66 KB
Format:
Adobe Portable Document Format
Description:
Main article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
STEM